



# ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH  
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH  
INVEST & PARTNERING



## Company Description

CARP Pharmaceuticals was founded to develop effective, affordable cancer treatments for millions worldwide. CARP Pharmaceutical lead compound was developed by Queensland University of Technology researchers. Based in Brisbane at the Translational Research Institute, the CARP team has identified a unique class of broad spectrum anticancer drugs that have the potential to treat a wide range of cancers, including lung, breast, prostate and pancreatic cancers

## Pipeline and Developments

CARP Pharmaceuticals lead compound DKLS02 is designed for the treatment of patients with either lung, breast, prostate or pancreatic cancers. The drug functions by switching off the cancer cells ability to repair damaged genetic material. This results in chromosomal fragmentation and cell death. As all cancers are genetically unstable this drug has broad specificity and does not require a companion diagnostic. DKLS02 has just completed preclinical testing and will enter toxicology studies in Q2 2018.


## What we are looking for:

CARP Pharmaceuticals is looking to identify potential medium and long-term partners to participate in the development of the existing drug pipeline.

## Contact:

Name: David Nelson  
Position: Managing Director  
Company: CARP Pharmaceuticals  
Address: GPO Box 2866 Brisbane, Queensland 4001 Australia  
Website: <http://www.carp-pharmaceuticals.com.au/>  
Phone: +61 403 777 687  
Email: [david.nelson@mantlegroup.com.au](mailto:david.nelson@mantlegroup.com.au)

For more information, please visit [www.australiabiotechinvest.com.au](http://www.australiabiotechinvest.com.au)

 Follow us for the latest event update #AusBioInv